SRR12202467
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.350
- E2F_TARGETS+0.340
- G2M_CHECKPOINT+0.260
- MYC_TARGETS_V1+0.260
- SPERMATOGENESIS+0.260
- PROTEIN_SECRETION+0.230
- ANDROGEN_RESPONSE+0.150
- KRAS_SIGNALING_DN+0.030
- APICAL_SURFACE+0.020
- TGF_BETA_SIGNALING+0.010
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.420
- INTERFERON_GAMMA_RESPONSE-0.380
- ALLOGRAFT_REJECTION-0.370
- TNFA_SIGNALING_VIA_NFKB-0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- INFLAMMATORY_RESPONSE-0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.320
- IL6_JAK_STAT3_SIGNALING-0.310
- APICAL_JUNCTION-0.300
- UV_RESPONSE_DN-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202470 | — | — | 0.872 |
| 2 | BS_A14Z8BBK | medulloblastoma | — | 0.869 |
| 3 | BS_TE0GVDNG | medulloblastoma | — | 0.858 |
| 4 | R354 | — | — | 0.852 |
| 5 | BS_61E80SD6 | medulloblastoma | — | 0.850 |
| 6 | BS_NKRYMHEP | medulloblastoma | — | 0.846 |
| 7 | BS_QPPPGYP4 | medulloblastoma | — | 0.844 |
| 8 | R158 | — | — | 0.843 |
| 9 | SRR33346963 | — | — | 0.837 |
| 10 | BS_W9AT0MR7 | medulloblastoma | — | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.010 | Inavolisib | — uncovered |